Generic drug
Midazolam price, strengths & recalls
Generic of Nayzilam
Pharmacies pay $38.17 for 100 mL of Midazolam 5 mg/mL injection this week, and from $11.32 to $73.41 across its 6 priced strengths and forms. 19 manufacturers make it. It is in shortage (unavailable). 3 recalls are ongoing. Its official label last changed on February 19, 2026.
Unavailable3 open recallsGeneric- Fair cash price
- $54.40
- Strengths
- 6
- Makers
- 19
- Updated
- Nov 11
Midazolam price by strength
What pharmacies pay for each strength and form this week (Nov 11, 2026), for the usual package. Choose one for its fair price, 52-week chart and makers.
| Strength and form | Per unit | Pharmacies pay | ||
|---|---|---|---|---|
| 14.3 mg/mL, 0.7 mL auto-injector | Not priced this week | |||
| 1 mg/mL injection | $0.2305 | $11.53 / 50 mL | ||
| 1 mg/mL, 2 mL injection | $0.2305 | $11.53 / 50 mL | ||
| 5 mg/mL injection | $0.3817 | $38.17 / 100 mL | ||
| 5 mg/mL, 1 mL injection | $1.22 | $12.20 / 10 mL | ||
| 5 mg/mL, 2 mL injection | $0.5662 | $11.32 / 20 mL | ||
| 2 mg/mL oral solution | $0.6221 | $73.41 / 118 mL | ||
Brand names of midazolam
A brand and its generic share the active ingredient; the generic is almost always far cheaper.
Supply status: shortages & recalls
Shortages
- Midazolam Hydrochloride Preservative Free, Injection, 5 mg/5 mL (1 mg/mL) Single Dose Glass Fliptop Vial Novaplus (NDC 0409-2305-50)Next Delivery: December 2027; Estimated Recovery: March 2028; Shortage per Manufacturer: Manufacturing Delay
- Midazolam Hydrochloride, Injection, 10 mg/10 mL (1 mg/mL) (NDC 0409-2587-05)Next Delivery: January 2027; Estimated Recovery: March 2027
- Midazolam Hydrochloride Preservative Free, Injection, 10 mg/2 mL (5 mg/mL) (NDC 0409-2308-02)Next Delivery: December 2026; Estimated Recovery: March 2027
- Midazolam Hydrochloride Preservative Free, Injection, 5 mg/mL Single Dose Glass Fliptop Vial Novaplus (NDC 0409-2308-49)
- Midazolam Hydrochloride, Injection, 25 mg/5 mL (5 mg/mL) (NDC 0409-2596-03)
- Midazolam Hydrochloride, Injection, 10 mg/2 mL (5 mg/mL) Single Dose Glass Fliptop Vial Novaplus (NDC 0409-2308-50)
- Midazolam Hydrochloride Preservative Free, Injection, 2 mg/2mL (1 mg/mL) (NDC 0409-2305-17)Next Estimated Delivery and Estimated Recovery: December 2026
- Midazolam Hydrochloride Preservative Free, Injection, 2 mg/2mL (1 mg/mL) (NDC 0409-0001-25)Limited Supply Available. Next Delivery: December 2026; Estimated Recovery: June 2027
- Midazolam Hydrochloride Preservative Free, Injection, 5 mg/mL (5 mg/mL) (NDC 0409-2308-01)Next Delivery and Estimated Recovery: December 2026
- Midazolam Hydrochloride Preservative Free, Injection, 5 mg/5 mL (1 mg/mL) (NDC 0409-2305-05)Limited Supply Available. Next Delivery: October 2026; Estimated Recovery: March 2027
- Midazolam Hydrochloride, Injection, 50 mg/10 mL (5 mg/mL) (NDC 0409-2596-05)
- Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 63323-412-25)Next release November 2026. Check wholesalers for inventory.
In a shortage, ask your pharmacist whether another strength, form or maker is in stock, and how much notice they need. What to do in a drug shortage.
Recalls
Showing the 6 most relevant of 43 - all recalls.
A recall names specific lots. Check the lot number on your package against the recall before you worry - and don't stop a medicine without asking your pharmacist. What to do if your medication is recalled.
What people paid for Midazolam
Bought it recently? Share the price, the pharmacy and how you paid - it's the most useful thing the next person can read.
Official label & what changed
These highlights do not include all the information needed to use MIDAZOLAM INJECTION safely and effectively. See full prescribing information for MIDAZOLAM INJECTION. MIDAZOLAM injection, for intramuscular use, CIV Initial U.S. Approval: 1985
WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; ABUSE, MISUSE, AND ADDICTION; and DEPENDENCE AND WITHDRAWAL REACTIONS
Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Monitor patients for respiratory depression and sedation [see Warnings and Precautions (5.1), Drug Interactions (7.1)].
The use of benzodiazepines, including midazolam, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose or death. Abuse and misuse of benzodiazepines commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes. Before prescribing Midazolam Injection and throughout treatment, assess each patient's risk for abuse, misuse, and addiction [see Warnings and Precautions (5.2)].
The continued use of benzodiazepines may lead to clinically significant physical dependence. The risks of dependence and withdrawal increase with longer treatment duration and higher daily dose. Although Midazolam Injection is indicated only for intermittent use [see Indications and Usage (1) and Dosage and Administration (2)], if used more frequently than recommended, abrupt discontinuation or rapid dosage reduction of Midazolam Injection may precipitate acute withdrawal reactions, which can be life-threatening. For patients using Midazolam Injection more frequently than recommended, to reduce the risk of withdrawal reactions, use a gradual taper to discontinue Midazolam Injection [see Warnings
and Precautions (5.3)].
WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; ABUSE, MISUSE, AND ADDICTION; and DEPENDENCE AND
WITHDRAWAL REACTIONS
See full prescribing information for complete boxed warning.
Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Monitor patients for respiratory depression and sedation. (5.1, 7.1)
The use of benzodiazepines, including midazolam, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose or death. Before prescribing Midazolam Injection and throughout treatment, assess each patient's risk for abuse, misuse, and addiction. (5.2)
Although Midazolam Injection is indicated only for intermittent use (1, 2), if used more frequently than recommended, abrupt discontinuation or rapid dosage reduction of Midazolam Injection may precipitate acute withdrawal reactions, which can be lifethreatening. For patients using Midazolam Injection more frequently than recommended, to reduce the risk of withdrawal reactions, use a gradual taper to discontinue Midazolam Injection. (5.3)
We check this label every day. When it changes, the sections that changed appear here, old text beside new.
We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.
Approval, patents & generics
- Application
- NDA216359 · Rafa Labs Ltd
- First approved
- August 8, 2022 (4 years ago)
- Latest approved change
- May 2, 2024
- Approved label
- PDF, Jun 18, 2024
- Generic makers
- 10 approved generic applications on the market
Midazolam questions
How much does midazolam cost without insurance?
Pharmacies pay about $38.17 for 100 mL of midazolam 5 mg/mL injection ($0.3817 per mL). A fair cash price - that cost plus a 15% margin and a typical dispensing fee - is about $54.40. If you're quoted much more, check your quote and ask for the pharmacy's cash price.
What is the brand name of midazolam?
Midazolam is sold as Nayzilam. The generic has the same active ingredient and usually costs far less.
Is midazolam in shortage?
Yes. 30 products are listed as in shortage or being discontinued (unavailable). See which ones.
Has midazolam been recalled?
43 recalls on record, 3 ongoing. Recalls name specific lots - check yours.
When did the midazolam label last change?
The official label was last updated on February 19, 2026 (version 5). See what changed.
Talk about midazolam
No comments yet. Questions, tips, what worked for you - start the conversation.